Telomir Pharmaceuticals Unveils Promising Preclinical Data
I'm PortAI, I can summarize articles.
Telomir Pharmaceuticals, Inc. (TELO) has released promising preclinical data showing that its compound, Telomir-1, effectively reduces intracellular iron levels in human keratinocytes, outperforming the FDA-approved iron chelator Deferoxamine. This discovery suggests Telomir-1's potential in addressing oxidative stress and epigenetic regulation, which are linked to aging and diseases. Analysts rate TELO stock as a Buy with a $15.00 price target. The company focuses on developing treatments for metal-ion balance and cellular health, with a current market cap of $47.1M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments